Skip to Content

Aptorum Group Ltd Class A APM

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Aptorum Group Ltd is a Hong Kong based pharmaceutical company currently in the preclinical stage, engaged in developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. The company is pursuing therapeutic and diagnostic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas. It also has projects focused on surgical robotics. The operating business segments are Therapeutics, and Non-Therapeutics segments. The company derives revenue from Healthcare service.

Contact
148 Connaught Road Central, 17th Floor, Guangdong Investment Tower
Hong Kong, Cayman Islands
T +852 21176611
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Dec 31, 2019
Stock Type
Employees 40